関連する実験動画
Updated: May 5, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
シムバスタチンとリファキシミンの非補償性肝硬変: ランダム化臨床試験
Elisa Pose1,2,3, César Jiménez4,5, Giacomo Zaccherini6,7
1Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
JAMA
|February 5, 2025
まとめ
シムバスタチンとリファキシンを併用した治療は,肝硬化症の患者のアウトカムを改善しませんでした. この試験では,プラセボと比較して重篤な合併症,臓器不全,または死亡率の有意な減少は認められなかった.
科学分野:
- ヘパトロジー
- 臨床試験
- 薬理学について
背景:
- 肝硬変の合併症は患者の治療結果に大きな影響を与える.
- 現在の治療法は重度の肝硬変の合併症を防ぐのに有効ではありません.
- シムバスタチンとリファキシミンは,肝硬変の治療において個別に潜在的な効果を示している.
研究 の 目的:
- 非補償性肝硬変の患者における結果改善におけるシンバスタチンとリファキシミンの組み合わせの有効性を評価する.
- 重篤な合併症と死亡率に対するこの併用療法の影響を評価する.
主な方法:
- 欧州の14の病院で,非補償性肝硬変の237人の患者を対象とした第3相,ダブルブラインド,プラセボ対照試験です.
- 患者は標準治療とシンバスタチン (20 mg/ d) とリファキシミン (1200 mg/ d) またはプラセボを12ヶ月間受けました.
- 主要エンドポイントは,急性/ 慢性肝不全の発生率であり,次要エンドポイントは,移植なしの生存率および複合性肝硬変の合併症でした.
主要な成果:
- シムバスタチン・リファキシミン群 (17. 9%) とプラセボ群 (14. 2%) の間で,急性/ 慢性肝不全の発生率に有意な違いは認められなかった.
- 移植または死亡率 (18. 8% 対 24. 2%) と肝硬変合併症の発生率 (42. 7% 対 45. 8%) もグループ間では類似していました.
- 治療群の3人の患者はラブドミオリスを患ったが,有害事象は比較可能であった.
結論:
- シムバスタチンとリファキシミンの組み合わせは,標準治療に追加された場合,肝硬化症の患者の臨床結果を改善しません.
- この患者集団の代替治療戦略を探るには,さらなる研究が必要になる可能性があります.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
Drugs for Treatment of Diarrhea-Predominant IBS
142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
Drugs for Treatment of Constipation-Predominant IBS
130
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
130
Esophageal Varices-II: Clinical Features and Management
37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37
Ultrasound II: Endoscopic Ultrasound and FibroScan
66
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
66

